Research identifies protein for slowing colorectal cancer subtype

Inhibiting the Jagged 1 protein in mice prevents the proliferation and growth of colon and rectal tumours, according to a study led by the Molecular Mechanisms of Cancer and Stem Cells research group from the Hospital del Mar Medical Research Institute (IMIM), directed by Dr Lluís Espinosa, who is also a member of CIBERONC (the Network Centre for Biomedical Research into Cancer), in collaboration with the Pathological Anatomy and Medical Oncology Units at Hospital del Mar, and the IDIBELL-Catalan Oncology Institute.

No survival benefit from current rectal cancer treatment recommendations for younger patients

Individuals younger than 50 years of age who are diagnosed with rectal cancer do not experience an overall survival benefit from currently recommended treatments, according to the study, ‘Rectal cancer patients under 50 years of age lack a survival benefit from NCCN guideline-directed treatment for stage II and III disease’, published in Cancer - a peer-reviewed journal of the American Cancer Society.

Two quality improvement programmes lead to fewer postoperative complications

Two pre-surgery checklists from the American College of Surgeons (ACS) Strong for Surgery (S4S) program that incorporate best practices for engaging patients in preparing for their upcoming operations, significantly improved lifestyle factors that pose an increased risk for postoperative complications or help support healing and postoperative recovery.

DOTA-PRIT nuclear medicine approach promising for treating cancerous tumours

A novel nuclear medicine approach is showing great promise for precision treatment of solid tumours in many types of cancer including lung, breast, pancreas and ovarian in adults and glioma, neuroblastoma and sarcoma in children. The research was presented at the SNMMI 2018 Annual Meeting, June 23-26 in Philadelphia.

Younger patients: No survival benefit from current CRC treatment recommendations

Patients younger than 50 years of age who are diagnosed with rectal cancer do not experience an overall survival benefit from currently recommended treatments, suggesting that early onset disease may differ from later onset disease in terms of biology and response to therapy, according to a study published in Cancer, a peer-reviewed journal of the American Cancer Society.

Study links blood vitamin D levels to colorectal cancer risk

A study authored by scientists from the American Cancer Society, the Harvard TH Chan School of Public Health, the US National Cancer Institute, and more than 20 other medical centres and organisations has reported that higher circulating vitamin D concentrations are significantly associated with lower colorectal cancer risk. This study strengthens the evidence, previously considered inconclusive, for a protective relationship.

Novel nuclear medicine shows promise for treating wide array of cancerous tumours

A novel nuclear medicine approach is showing great promise for precision treatment of solid tumours in many types of cancer including colorectal cancer, lung, breast, pancreas and ovarian in adults and glioma, neuroblastoma and sarcoma in children. The research was presented at the SNMMI 2018 Annual Meeting, June 23-26 in Philadelphia.